Last edition
News about "Merck ENFLONSIA"
US FDA Accepts sBLA for ENFLONSIA to Expand RSV Indication
US Food and Drug Administration (FDA) and European Medicines Agency (EMA) accept applications for ENFLONSIA (clesrovimab-cfor) to expand RSV protection for high-risk children under 2 years of age during their second Respiratory Syncytial Virus (RSV) season.
Merck ENFLONSIA | 07/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members